Advanced

Malignancy as a comorbidity in rheumatic diseases.

Turesson, Carl LU and Matteson, Eric L (2013) In Rheumatology (Oxford, England) 52(1). p.5-14
Abstract
Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into... (More)
Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Rheumatology (Oxford, England)
volume
52
issue
1
pages
5 - 14
publisher
Oxford University Press
external identifiers
  • wos:000312640300003
  • pmid:22829694
  • scopus:84871146837
ISSN
1462-0332
DOI
10.1093/rheumatology/kes189
language
English
LU publication?
yes
id
15d594af-67db-40a8-9ec0-22fb7d3df685 (old id 2966664)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22829694?dopt=Abstract
date added to LUP
2012-08-10 08:20:20
date last changed
2019-09-17 02:29:47
@article{15d594af-67db-40a8-9ec0-22fb7d3df685,
  abstract     = {Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients.},
  author       = {Turesson, Carl and Matteson, Eric L},
  issn         = {1462-0332},
  language     = {eng},
  number       = {1},
  pages        = {5--14},
  publisher    = {Oxford University Press},
  series       = {Rheumatology (Oxford, England)},
  title        = {Malignancy as a comorbidity in rheumatic diseases.},
  url          = {http://dx.doi.org/10.1093/rheumatology/kes189},
  volume       = {52},
  year         = {2013},
}